4.22
0.04 (0.96%)
| Previous Close | 4.18 |
| Open | 4.19 |
| Volume | 5,821,566 |
| Avg. Volume (3M) | 4,391,198 |
| Market Cap | 951,842,112 |
| Price / Book | 4.55 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Diluted EPS (TTM) | -0.880 |
| Total Debt/Equity (MRQ) | 43.67% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -206.18 M |
| Levered Free Cash Flow (TTM) | -118.45 M |
| Return on Assets (TTM) | -23.84% |
| Return on Equity (TTM) | -71.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Sana Biotechnology, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.46% |
| % Held by Institutions | 89.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Crestline Management, Lp | 31 Mar 2025 | 2,790,937 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 12.00 (Morgan Stanley, 184.36%) | Buy |
| Median | 11.00 (160.66%) | |
| Low | 5.00 (JMP Securities, 18.48%) | Buy |
| Average | 9.33 (121.09%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 03 Jul 2025 | 12.00 (184.36%) | Buy | 3.19 |
| JMP Securities | 24 Jun 2025 | 5.00 (18.48%) | Buy | 2.97 |
| HC Wainwright & Co. | 24 Apr 2025 | 11.00 (160.66%) | Buy | 1.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Jun 2025 | Announcement | Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression |
| 09 Jun 2025 | Announcement | Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions |
| 28 May 2025 | Announcement | Sana Biotechnology to Present at June 2025 Investor Conferences |
| 12 May 2025 | Announcement | Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference |
| 08 May 2025 | Announcement | Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |